Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Carbapenem-Resistant Bacteria Recovered from Faeces of Dairy Cattle in the High Plains Region of the USA

  • Hattie E. Webb,

    Affiliation International Center for Food Industry Excellence, Department of Animal and Food Sciences, Texas Tech University, Lubbock, Texas, United States of America

  • Marie Bugarel,

    Affiliation International Center for Food Industry Excellence, Department of Animal and Food Sciences, Texas Tech University, Lubbock, Texas, United States of America

  • Henk C. den Bakker,

    Affiliation International Center for Food Industry Excellence, Department of Animal and Food Sciences, Texas Tech University, Lubbock, Texas, United States of America

  • Kendra K. Nightingale,

    Affiliation International Center for Food Industry Excellence, Department of Animal and Food Sciences, Texas Tech University, Lubbock, Texas, United States of America

  • Sophie A. Granier,

    Affiliation Antimicrobial Resistance Unit, Laboratory for Food Safety, ANSES, Paris-Est University, Maisons-Alfort Cedex, France

  • H. Morgan Scott,

    Affiliation Department of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, United States of America

  • Guy H. Loneragan

    Affiliation International Center for Food Industry Excellence, Department of Animal and Food Sciences, Texas Tech University, Lubbock, Texas, United States of America

Carbapenem-Resistant Bacteria Recovered from Faeces of Dairy Cattle in the High Plains Region of the USA

  • Hattie E. Webb, 
  • Marie Bugarel, 
  • Henk C. den Bakker, 
  • Kendra K. Nightingale, 
  • Sophie A. Granier, 
  • H. Morgan Scott, 
  • Guy H. Loneragan



A study was conducted to recover carbapenem-resistant bacteria from the faeces of dairy cattle and identify the underlying genetic mechanisms associated with reduced phenotypic susceptibility to carbapenems.


One hundred and fifty-nine faecal samples from dairy cattle were screened for carbapenem-resistant bacteria. Phenotypic screening was conducted on two media containing ertapenem. The isolates from the screening step were characterised via disk diffusion, Modified Hodge, and Carba NP assays. Carbapenem-resistant bacteria and carbapenemase-producing isolates were subjected to Gram staining and biochemical testing to include Gram-negative bacilli. Whole genome sequencing was performed on bacteria that exhibited either a carbapenemase-producing phenotype or were not susceptible to ertapenem and were presumptively Enterobacteriaceae.


Of 323 isolates collected from the screening media, 28 were selected for WGS; 21 of which were based on a carbapenemase-producing phenotype and 7 were presumptively Enterobacteriaceae and not susceptible to ertapenem. Based on analysis of WGS data, isolates included: 3 Escherichia coli harbouring blaCMY-2 and truncated ompF genes; 8 Aeromonas harbouring blacphA-like genes; 1 Acinetobacter baumannii harbouring a novel blaOXA gene (blaOXA-497); and 6 Pseudomonas with conserved domains of various carbapenemase-producing genes.


Carbapenem resistant bacteria appear to be rare in cattle. Nonetheless, carbapenem-resistant bacteria were detected across various genera and were found to harbour a variety of mechanisms conferring reduced susceptibility. The development and dissemination of carbapenem-resistant bacteria in livestock would have grave implications for therapeutic treatment options in human medicine; thus, continued monitoring of carbapenem susceptibility among enteric bacteria of livestock is warranted.


Carbapenems have become increasingly important as infections caused by pathogenic bacteria resistant to practically all alternative antibiotics have become globally disseminated throughout the past two decades [1, 2]. It is for this reason that carbapenems are reserved as the last resort treatment of multi-drug resistant (MDR) infections in humans. Consequently, the spread of carbapenem-hydrolysing enzymes among Enterobacteriaceae in hospital settings is of grave concern [35]. Saliently, an estimated 9,300 healthcare-associated infections due to carbapenem-resistant Klebsiella and E. coli occurr in the United States (US) annually [6]. It is likely that the emergence and dissemination of carbapenem-resistant Enterobacteriaceae (CRE) is the consequence of increased reliance on carbapenems for treatment of MDR infections. Moreover, carbapenem resistance has become an urgent public health concern largely because CRE are commonly co- or cross- resistant to all other clinically relevant antimicrobials; this, in turn, drastically limits—or eliminates—alternative therapeutic options [6, 7].

Carbapenem resistance is generally mediated by two primary mechanisms: (i) production of carbapenemases, enzymes (e.g. KPC, VIM, and OXA) capable of hydrolysing almost all β-lactams or (ii) through modifications to the cell outer membrane, specifically by decreased cell membrane permeability from porin modification, and/or production of efflux pumps; this is often found in combination with cephalosporinase enzymes [7]. Carbapenemases are classified into four different classes (Ambler classes A, B, C, and D) based on their mechanism of antibiotic hydrolysis [8]. The extent of resistance varies among enzymes in that KPC-1 and IMP-1 are commonly associated with resistance to typical therapeutic concentrations of carbapenems, whereas OXA-23 is commonly associated with a reduced susceptibility to carbapenems based on clinical interpretive criteria [9, 10].

In addition to clonal dissemination of CRB, carbapenemase-encoding genes are frequently carried by mobile genetic elements, such as plasmids, and, as a result, carbapenemase encoding genes have been reported across a variety of Enterobacteriaceae genera [11, 12]. Most clinically relevant carbapenem resistance appear to have arisen and propagated as a result of clinical carbapenem use in human medicine [13]; consequently, our knowledge concerning the epidemiology and ecology of carbapenem-resistant bacteria (CRB) is largely limited to human clinical settings.

Carbapenems are not approved for use in livestock production anywhere in the world [14]; as a result, food-animal use is assumed to be rare. Despite—or perhaps because of—the lack of direct selection pressure, little is known about the prevalence of CRB, and more specifically CRE, in livestock populations and their associated environments. Even though there remains a low probability of direct selection, CRB have been reported by investigators in a few instances; for example blaVIM-1 was detected in Salmonella recovered from fattening pig farms and a broiler farm in Germany [15], blaOXA-23 was detected in Acinetobacter isolated from dairy cattle in France and horses in Belgium [16, 17], and blaNDM-1 was detected in Acinetobacter isolates from a chicken farm and from pigs in China [18, 19]. Despite robust existing integrated antimicrobial resistance surveillance systems, surveillance of carbapenem resistance among bacteria of livestock origin is in preliminary stages [20]. Given the high prevalence of co-resistance to other antimicrobial classes among most clinically relevant CREs, it seems highly plausible that, if introduced into livestock populations, CRE would further disseminate to humans through animal contact, the environment, or food. It is important, therefore, to investigate agricultural systems to detect and characterise carbapenem resistance among bacteria of animal origin. The objectives of this project was to recover carbapenem-resistant bacteria (CRB) from the faeces of dairy cattle and identify the underlying genetic mechanisms associated with reduced phenotypic susceptibility to carbapenems.

Materials and Methods

Faecal sample collection

Pen-surface faecal samples were collected from a convenience sample of a dairy farm located in southeastern New Mexico, US, and another dairy farm in the Texas Panhandle, US. Permission from the owner of the private operations was received. As pen-floor fecal samples were collection, there was no interaction with vertebrate animals and no approval from an Institutional Animal Care and Use Committee was needed. These dairy farms reported frequent historical use of ceftiofur (a 3rd generation cephalosporin) and we have observed widespread prevalence of genes encoding for AmpC and extended spectrum beta-lactamase (ESBL) enzymes among Enterobacteriaceae (unpublished data). Samples were collected on multiple days from May to July 2014 from pens housing healthy cows in early lactation (maximum 50 days in milk).

Selective isolation of CRB

Twenty-five grams of faeces were enriched in 225 mL of MacConkey broth (EMD Millipore, Darmstadt, Germany) containing ertapenem (0.5 mg/L; Toronto Research Chemicals, Inc., Toronto, Canada), which was then hand homogenised before incubation at 37°C for 18 to 22 hours. Following incubation, 10 μL was streaked to two agar plates as an initial screening method for CRB, one MacConkey agar (EMD Millipore) plate containing ertapenem (1.0 mg/L; ME) and one modified-SUPERCARB (SC) agar plate. The ME agar was prepared as previously described by Nordmann, Girlich, and Poirel [21]; however, due to the unavailability of Drigalski agar, MacConkey agar instead was used in the SC agar. In addition, the concentration of ertapenem was raised from 0.25 mg/L to 0.5 mg/L, to reflect a change in interpretive criteria for ertapenem [10].

Phenotypic characterisation of CRB

One colony of each unique morphology was selected and streaked for isolation on tryptic soy agar (EMD Millipore) containing ertapenem (0.5 mg/L; TSAe), which was then incubated for 18 to 22 hours at 37°C (S1 Fig). Isolates from the TSAe were screened in parallel utilising the Modified Hodge test (MHT) and disk diffusion (DD) susceptibility test with an ertapenem-containing disk (10 μg, BD BBL Sensi-Disc™, Sparks, MD) as previously described [10]. Isolates were further characterised if they exhibited enhanced growth on MHT or else were not susceptible to ertapenem using the Clinical and Laboratory Standards Institute (CLSI) DD interpretive criteria for Enterobacteriaceae, the initial genera targeted [10]. Intermediate and true clinical resistance according to CLSI criteria will herein be described as resistance for simplicity. A Gram stain was performed and presumptive species identification was obtained on all Gram-negative bacilli using biochemical identification test kits specific for Enterobacteriaceae (API 20E strips, Biomérieux, Marcy-l’Etoile, France) and Gram-negative organisms (Sensititre GNID, TREK Diagnostic Systems Inc., Cleveland, OH). To confirm the carbapenemase-positive phenotype, a pH-based test (Carba NP) was performed to confirm hydrolysis of the carbapenem β-lactam as previously described [22]. Following genotypic exploration of genus (described below), the DD results were later reinterpreted using the appropriate criteria where available (as indicated in Table 1) [10]. As criteria have not yet been established for some complexes of Aeromonas or for Pseudomonas spp. other than P. aeruginosa, CLSI criteria that are available were used for reinterpretation of the A. allosaccharophila and Pseudomonas spp. isolates reported herein. These values are not meant to imply clinical efficacy, but were interpreted to serve as a phenotypic description in reference to better described relatives.

Table 1. Phenotypic and genotypic description of the carbapenemase-producing or ertapenem non-susceptible isolates from dairy cattle faeces that were subjected to WGS.

WGS and bioinformatics analyses

Whole-genome sequencing was performed for: (i) all potential CRE from all screening methods; and (ii) isolates of other families with a carbapenemase-producing phenotype (S1 Fig). Genomic DNA was extracted (Bacterial Genomic Miniprep kit, Sigma-Aldrich, St. Louis, MO), and paired-end libraries were generated (Nextera XT library kit v2, Illumina Inc., San Diego, CA). The resulting libraries were sequenced using the sequencing by synthesis method on an Illumina sequencing platform (MiSeq V.3.0, Illumina Inc., San Diego, CA) to obtain 300 bp reads. A targeted genome coverage of 65x was used given an assumed mean genome size of 5 Mb for 28 isolates per run. Reads were assembled into draft genomes (A5 pipeline [23]) and preliminarily annotated (Prokka [24]). The National Center for Biotechnology Information Prokaryotic Genome Annotation Pipeline (NCBI PGAP [September 23, 2015]) was used for the final genome annotation. Species identification was performed by calculating the average nucleotide identity (ANIb) values between draft genomes obtained in this study and publicly available reference genomes (JSpecies v1.2.1 [25]), and additional phylogenetic confirmation using 16S sequences from draft genomes sequenced at Texas Tech University were compared to type strains from the Ribosomal Database Project ( Acinetobacter baumannii and Escherichia coli isolates were further typed by multi-locus sequence typing (MLST; MLST 1.8, Center for Genomic Epidemiology [CGE], Lyngby, Denmark). Isolates were screened for antimicrobial resistance genes (SRST2 [26]) using the Antibiotic Resistance Gene-ANNOTation tool (ARG-ANNOT [27]) database and the online tool ResFinder 2.1 ( [28]). Where no putative mechanisms of carbapenem resistance were identified, conserved domain BLASTs were performed using the Integrated Toolkit for Exploration of microbial Pan-genomes (ITEP [29]) in order to identify conserved domains associated with antibiotic resistance genes in other prokaryotes.

Outer membrane protein (OMP) gene sequences, specifically the ompF and ompC, were extracted from the E. coli draft genomes sequenced in this study, as well as from a number of reference genomes (Genbank U00096.3, CP008957.1, CP009072.1, NC_013361.1, and HG428755.1). The OMP genes of the carbapenem-resistant E. coli were compared to the OMP genes of the reference genomes to order to identify possible mutations, truncations, and insertions that might affect protein function.


From 159 faecal samples, a total of 151 and 172 isolates were collected from the SC and ME plates, respectively. Of these 323 isolates, 163 isolates were deemed of interest as follows: 6 demonstrated a carbapenemase-producing phenotype on the MHT but were ertapenem-susceptible via DD, 142 were ertapenem-resistant via DD, and 15 demonstrated a carbapenemase-producing, ertapenem-resistant phenotype. All DD interpretations at this stage were completed utilising the CLSI Enterobacteriaceae interpretive criteria as a screening method [10]. Within these isolates of interest, 131 were Gram-negative bacilli and, by using the selection criteria (S1 Fig), 28 isolates from 21 pen-surface samples were selected for characterisation by WGS. Twenty-one of the 28 isolates were selected based on a carbapenemase-producing phenotype (regardless of its biochemical characterisation) and 7 presumptive CRE based on DD. Of the isolates selected for WGS, a total of 17 and 11 isolates were collected from SC and ME agar plates, respectively.

As a majority of the biochemical results lacked single genera exclusivity in their results (data not reported), genome interrogation was used for final speciation; the isolates included Aeromonas spp. (n = 18), A. baumannii (n = 1), Pseudomonas spp. (n = 6), and E. coli (n = 3; Table 1). The sequence types (ST) of all E. coli isolates (n = 3) were identical; that is, either ST-227 (n = 3) or ST-638 (n = 3) depending on the typing scheme used, Oxford or Pasteur [30, 31], respectively. All 3 E. coli isolates harboured the AmpC β-lactamase gene blaCMY-2. Comparison of the ompF gene sequences in all 3 E. coli isolates to reference sequences revealed a single base pair insertion at position 373 that resulted in a frameshift and; thus, a predicted premature stop codon in the protein leading to a truncated 128 amino acid OmpF (compared to 362 amino acids of the reference strains). Two of the three E. coli isolates (120BME and 121AME) showed 100% similarity in their ompC amino acid sequences and no predicted premature stop codons were identified. The genomic region containing ompC in the remaining E. coli isolate (148AME) could not be adequately assembled.

A carbapenemase-producing phenotype was observed in the single A. baumannii and this isolate was of a novel ST designated ST-1133 and ST-742 based on the Oxford [32] and Pasteur [33] scheme, respectively (PubMLST database;, date: October 21, 2015 and September 11, 2015). This isolate harboured an Ambler class D carbapenemase that is part of the OXA-51-like enzyme group (S3 Fig) with 5 nucleotide changes that yield 3 amino acid changes (N111D, D123N, and E227G) from the previously described blaOXA-379 (KF986260). The observed blaOXA β-lactamase gene appeared to be novel and was designated blaOXA-497 (Lahey β-lactamase database;, date: July 8, 2015). It was found in a contig that has high sequence similarity to the sequence of chromosome A. baumannii CIP70.10 (LN865143.1) and genes flanking blaOXA-497 did not show similarity to transposable elements (e.g. insertion sequences). The isolate exhibited intermediate resistance to ertapenem using clinical interpretive DD criteria for the Acinetobacter spp [10].

Eighteen Aeromonas isolates were sequenced; 17 harboured a carbapenemase-producing phenotype that was initially observed on the MHT and was subsequently confirmed with the Carba NP assay. The remaining isolate showed biochemical and phenotypic characteristics of a CRE. Following genome sequencing, 17 isolates were identified as A. veronii and one isolate as A. allosaccharophila; the latter isolate exhibited a carbapenemase-producing phenotype, but was susceptible to ertapenem via DD using interpretive criteria for Aeromonas spp. of the A. caviae, A. hydrophila, and A. veronii complexes [34]. All of the A. veronii isolates harboured a blacphA-like gene in a highly conserved part of the chromosome, although three allele variations of this gene were identified (S2 Fig).

Of the 6 Pseudomonas isolates, 2, 3 and 1 were identified as P. citronellolis, a putatively undescribed species closely related to P. stutzeri, and a putatively undescribed species closely related to P. anguillispectica, respectively. Three of these Pseudomonas isolates were considered of interest due to presumptive carbapenemase production (008ASC, 011ASC, and 105ASC), while the remaining three were speculated to be presumptive CRE based on disk diffusion and biochemical characterisation. The initial biochemical findings suggested the possibility that they belonged to the Enterobacteriaceae family; however, these were subsequently identified as Pseudomonas spp. based on analysis of sequence data. When utilising the interpretative criteria for P. aeruginosa, the non-carbapenemase-producing isolates had a reduced susceptibility to ertapenem, whereas those with a carbapenemase-positive phenotype exhibited susceptibility. Identified conserved domains of genes included those encoding Ambler class B (blaIMP), class C (blaampC), and class D (blaOXA) β-lactamases; yet their role in the observed phenotypes remains uncertain (S1 Table).


In this study, we recovered CRB from cattle faeces. Whereas we did not attempt to identify dissemination beyond the dairy farms, our find warrants further consideration of the diversity of CRB on dairies. We selected the 2 dairy farms based on frequent ceftiofur use and previously observed frequency of AmpC and ESBL gene harbourage among Enterobacteriaceae bacteria (unpublished data). We hypothesised, therefore, that the selective pressure of ceftiofur use [35] may have favoured dissemination of these β-lactamases and might also select for carbapenemases, if present. While our report is not intended to be generalised to the wider population of dairy cattle, it does provide novel insights into the diversity of carbapenem-resistance mechanisms and the diversity of bacteria that harbour them in agricultural environments.

Our initial goal was to detect carbapenem resistance among Enterobacteriaceae and we were able to identify 3 CRE isolates of E. coli species from 159 samples; hence, we conclude that the burden of CRE is extremely low. Moreover, these CRE were negative for carbapenemase production and their expressed phenotypic resistance might be due to a multifactorial mechanism. The combined presence of blaCMY-2 and a lack of OmpF and OmpC have been previously associated with imipenem resistance in E. coli [36, 37]; however, a more recent report refutes the involvement of OmpC in carbapenem-resistance and suggests that there may be other unknown mechanisms [38]. In the recovered E. coli, we were able to confirm the presence of a blaCMY-2 and a premature stop codon in the ompF; although the clinical importance of these carbapenemase-negative CRE to human health outcomes remains uncertain.

While not included in our initial goal, we also identified carbapenemase-producing bacteria among non-Enterobacteriaceae families. These were included based on our decision tree (S1 Fig); for some, biochemical test results indicated the possibility that these isolates belonged to the Enterobacteriaceae family. While our biochemical assays might not always have provided conclusive identification, it enabled us to characterise carbapenemase enzymes or carbapenem-resistance among a diverse set of bacteria. In particular, we recovered an A. baumannii harbouring a novel blaOXA gene (blaOXA-497) that appears to be chromosomally encoded, thus presumably likely to be transferred than if associated with genetic mobile elements, such as plasmids or insertion sequences. Carbapenemase activity by blaOXA enzymes can vary as the activity can depend on the extent of gene expression and/or the presence of other resistance mechanisms, such as decreased permeability or efflux [39]. Future investigations to characterise this isolate and to describe the potential mobilisation of blaOXA-497 and its extent of expression are underway. In addition to A. baumannii, we recovered many Aeromonas isolates harbouring a blacphA-type metallo-β-lactamase, which are reported to be common among A. veronii [40, 41]. The genes encoding cphA-type enzymes are on the chromosome; thus, they might be of less epidemiologically relevance to the dissemination of genes that hydrolyse carbapenems.

In some of the recovered Pseudomonas isolates, conserved domains of blaIMP- and blaOXA-like genes were identified that could represent an acquired ability to produce carbapenemases of clinical importance. Compared to P. aeruginosa, little is known about antimicrobial resistance in other species of Pseudomonas; thus, it is difficult to make inferences regarding the potential clinical importance of these isolates [10, 42]. Furthermore, there are no clinical interpretive criteria for pseudomonads other than P. aeruginosa. Interestingly, the presence of conserved domains of carbapenemase-producing phenotype did not always align with the carbapenemase-producing phenotype. While we find proteins with these conserved domains, these proteins appear to have a different function. This could also be due to a discrepancy in the phenotypic result or the presences of unidentified mechanisms conferring carbapenemase production [43, 44].

An important consideration is that universally accepted phenotypic methods to recover and characterise carbapenem resistant (or at least, non-susceptible) bacteria are in early stages of development and, thus, limitations were inherent in the methods used in our study. First, the concentration of ertapenem in the enrichment and selective media may have been too great for isolation of some carbapenemase-producing bacteria; in particular, bacteria producing OXA-like enzymes that have been associated with low-level resistance—due to their weak ability to hydrolyse carbapenems—might not have been recovered [45, 46]. In addition, as our scope of interest broadened posteriori to include Aeromonas spp., Acinetobacter spp., and Pseudomonas spp., screening with an alternative carbapenem may have been more appropriate as ertapenem exhibits poor activity on the latter two genera [43, 47]. Finally, the carbapenemase screening method used (the MHT) has been associated with interpretation challenges that include both false-positive and false-negative results [10, 48, 49]. In this study, the Carba NP test was used to confirm carbapenemase production after the MHT; however, it is possible that some carbapenemase-producing bacteria may have been wrongfully disregarded due to interpretation error on the MHT.

Based on the results described herein—and despite the limitations of the study, CRE appear to be very rare among dairy cattle in the High Plains of the USA. Nevertheless, CRB were present in the dairy cattle population sampled. Importantly, many of the carbapenemase genes recognised for their rapid acquisition and dissemination throughout hospital-settings worldwide, e.g. variants of blaKPC or blaNDM [50], were not found. Despite this, we described a diverse set of bacteria and mechanisms that conferred resistance to carbapenems. These results, therefore, highlight the need for effective approaches to avoid the introduction of clinically relevant genetic elements into cattle populations, and to prevent the emergence of carbapenem resistant determinants in livestock populations through co-selection with other commonly used antimicrobials. Further, we believe there is need for on-going or periodic surveillance of CRB in livestock populations. Clearly, this is contingent on the development of methods with sensitivity and specificity for all types of carbapenemase enzymes. Molecular methods may offer advantages as alternative approaches for the detection of antimicrobial resistance genes; however, given the diversity of genetic mechanisms identified, isolate-based genomic interrogation is still warranted.

Supporting Information

S1 Fig. Decision tree used to determine inclusion criteria for carbapenem-resistant isolates collected from dairy cattle faeces.



S2 Fig. Phylogeny demonstrating variation of cphA gene in Aeromonas isolates found in this study.

Sequences of cphA were aligned using Muscle version 3.8.31 (Edgar, RC. 2004. Nucleic Acids Research, 32(5), 1792–1797) and a parsimony based phylogeny was inferred using PAUP*version 4.0b10 (Wilgenbusch, J. C., & Swofford, D. (2003). Current Protocols in Bioinformatics / Editoral Board, Andreas D Baxevanis [Et Al], Chapter 6, Unit 6.4. bi0604s00), using the heuristic search option. Values on the branches are the inferred number of steps (single nucleotide substitutions). The search resulted in 1 tree (317 steps, C.I. = 0.647). Values below the branches indicate bootstrap values based on 500 replicates, values below < 50 are not shown.



S3 Fig. Maximum likelihood phylogenies of representative OXA- types and OXA-51-like nucleotide sequences (inset) including the novel OXA-497 (marked in red).

Nucleotide sequences were aligned using an amino acid sequence guided strategy using TranslatorX (Abascal et al. 2010. Nucleic Acids Research, 38 Web Server issue), W7–13., phylogenies were inferred using RAxML version 8.1.20 (Stamatakis, A. 2014. Bioinformatics 30(9), 1312–1313. Values on the branches represent bootstrap values as inferred using the autoFC bootstopping option (Pattengale et al. 2010, Journal of Computational Biology: a Journal of Computational Molecular Cell Biology, 17(3), 337–354.



S1 Table. Overview of putative beta-lactamase like genes in Pseudomonas spp. found by conserved domain searches.




We thank Patrice Nordmann for his advice on the Carba NP test. We also thank the team of curators of the Institut Pasteur Acinetobacter MLST system for curating the data and making them publicly available at

Author Contributions

Conceived and designed the experiments: HEW GHL HMS. Performed the experiments: HEW KKN MB. Analyzed the data: HCB MB. Wrote the paper: SAG.


  1. 1. Livermore D. The zeitgeist of resistance. J Antimicrob Chemother. 2007;60:I59–I61. doi: 10.1093/jac/dkm160. WOS:000249117800011. pmid:17656385
  2. 2. Carattoli A. Animal reservoirs for extended spectrum beta-lactamase producers. Clin Microbiol Infect. 2008;14:117–23. doi: 10.1111/j.1469-0691.2007.01851.x. WOS:000252214500013. pmid:18154535
  3. 3. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae. Morb Mortal Weekly Rep. 2013;62:165–70.
  4. 4. European Centers for Disease Control and Prevention (ECDC). Antimicrobial resistance surveillance in Europe 2013 2014. Available from:
  5. 5. Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413–31. doi: 10.1111/j.1469-0691.2012.03821.x. WOS:000302903900011. pmid:22507109
  6. 6. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States Atlanta2013. Available from:
  7. 7. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infect Dis. 2011;17:1791–8. doi: 10.3201/eid1710.110655. pmid:22000347
  8. 8. Bush K. The ABCD's of beta-lactamase nomenclature. J Infect Chemother. 2013;19(4):549–59. doi: 10.1007/s10156-013-0640-7. WOS:000323078000001. pmid:23828655
  9. 9. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–72. doi: 10.1016/j.molmed.2012.03.003. pmid:22480775
  10. 10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. M100–S23 Cd, editor. Wayne, PA: CLSI; 2013.
  11. 11. Kochar S, Sheard T, Sharma R, Hui A, Tolentino E, Allen G, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2009;30(5):447–52. doi: 10.1086/596734. WOS:000264896800007. pmid:19301985
  12. 12. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52(7):848–55. doi: 10.1093/cid/cir025. WOS:000288802600006. pmid:21317398
  13. 13. Poirel L, Stephan R, Perreten V, Nordmann P. The carbapenemase threat in the animal world: the wrong culprit. J Antimicrob Chemother. 2014;69(7):2007–8. doi: 10.1093/jac/dku054. pmid:24576948
  14. 14. World Organization for Animal Health (OIE). OIE list of antimicrobial agents of veterinary medicine 2015 [cited 2015 August]. Available from:
  15. 15. Fischer J, Rodriguez I, Schmoger S, Friese A, Roesler U, Helmuth R, et al. Salmonella enterica subsp enterica producing VIM-1 carbapenemase isolated from livestock farms. J Antimicrob Chemother. 2013;68(2):478–80. doi: 10.1093/jac/dks393. WOS:000313652700036. pmid:23034713
  16. 16. Poirel L, Bercot B, Millemann Y, Bonnin RA, Pannaux G, Nordmann P. Carbapenemase-producing Acinetobacter spp. in cattle, France. Emerging Infect Dis. 2012;18(3):523–5. doi: 10.3201/eid1803.111330. WOS:000301024000032. pmid:22377480
  17. 17. Smet A, Boyen F, Pasmans F, Butaye P, Martens A, Nemec A, et al. OXA-23-producing Acinetobacter species from horses: a public health hazard? J Antimicrob Chemother. 2012;67(12):3009–10. doi: 10.1093/jac/dks311. WOS:000311312100039. pmid:22872446
  18. 18. Wang Y, Wu CM, Zhang QJ, Qi J, Liu HB, Wang Y, et al. Identification of new delhi metallo-beta-lactamase 1 in Acinetobacter Iwoffii of food animal origin. PLoS One. 2012;7(5):6. doi: 10.1371/journal.pone.0037152 WOS:000305343500066.
  19. 19. Zhang WJ, Lu ZJ, Schwarz S, Zhang RM, Wang XM, Si W, et al. Complete sequence of the bla(NDM-1)-carrying plasmid pNDM-AB from Acinetobacter baumannii of food animal origin. J Antimicrob Chemother. 2013;68(7):1681–2. doi: 10.1093/jac/dkt066. WOS:000320452200034. pmid:23449827
  20. 20. The European Commission. 2013/652/EU Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria. Official Journal of the European Union. 2013:L303/26-L/39.
  21. 21. Nordmann P, Girlich D, Poirel L. Detection of carbapenemase producers in Enterobacteriaceae by use of a novel screening medium. J Clin Microbiol. 2012;50(8):2761–6. doi: 10.1128/JCM.06477-11. pmid:22357501
  22. 22. Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerging Infect Dis. 2012;18(9):1503–7. doi: 10.3201/eid1809.120355. WOS:000307989700021. pmid:22932472
  23. 23. Tritt A, Eisen JA, Facciotti MT, Darling AE. An integrated pipeline for de novo assembly of microbial genomes. PLoS One. 2012;7(9):9. doi: 10.1371/journal.pone.0042304 WOS:000308788700005.
  24. 24. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068–9. doi: 10.1093/bioinformatics/btu153. pmid:24642063
  25. 25. Richter M, Rossello-Mora R. Shifting the genomic gold standard for the prokaryotic species definition. Proc Natl Acad Sci U S A. 2009;106(45):19126–31. doi: 10.1073/pnas.0906412106. pmid:19855009
  26. 26. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, et al. SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. Genome Med. 2014;6:16. doi: 10.1186/s13073-014-0090-6 WOS:000345714900001.
  27. 27. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, et al. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob Agents Chemother. 2014;58(1):212–20. WOS:000329581100027. doi: 10.1128/AAC.01310-13. pmid:24145532
  28. 28. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67(11):2640–4. doi: 10.1093/jac/dks261. WOS:000309923800014. pmid:22782487
  29. 29. Benedict MN, Henriksen JR, Metcalf WW, Whitaker RJ, Price ND. ITEP: An integrated toolkit for exploration of microbial pan-genomes. BMC Genomics. 2014;15:11. doi: 10.1186/1471-2164-15-8 WOS:000329614900002.
  30. 30. Wirth T, Falush D, Lan RT, Colles F, Mensa P, Wieler LH, et al. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol. 2006;60(5):1136–51. doi: 10.1111/j.1365-2958.2006.05172.x. WOS:000237423300006. pmid:16689791
  31. 31. Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, et al. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics. 2008;9:14. doi: 10.1186/1471-2164-9-560 WOS:000264106600001.
  32. 32. Bartual SG, Seifert H, Hippler C, Luzon MAD, Wisplinghoff H, Rodriguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005;43(9):4382–90. doi: 10.1128/jcm.43.9.4382-4390.2005. WOS:000232020400012. pmid:16145081
  33. 33. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One. 2010;5(3):17. doi: 10.1371/journal.pone.0010034 WOS:000276454000008.
  34. 34. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline— second edition. Wayne, PA: CLSI; 2010.
  35. 35. Lowrance TC, Loneragan GH, Kunze DJ, Platt TM, Ives SE, Scott HM, et al. Changes in antimicrobial susceptibility in a population of Escherichia coli isolated from feedlot cattle administered ceftiofur crystalline-free acid. Am J Vet Res. 2007;68(5):501–7. doi: 10.2460/ajvr.68.5.501. WOS:000246229600008. pmid:17472449
  36. 36. Poirel L, Heritier C, Spicq C, Nordmann P. In vivo acquistion of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol. 2004;42(8):3831–3. pmid:15297541
  37. 37. Low AS, MacKenzie FM, Gould IM, Booth IR. Protected environments allow parallel evolution of a bacterial pathogen in a patient subjected to long-term antibiotic therapy. Mol Microbiol. 2001;42(3):619–30. pmid:11722730
  38. 38. Lou HB, Chen M, Black SS, Bushell SR, Ceccarelli M, Mach T, et al. Altered antibiotic transport in OmpC mutants isolated from a series of clinical strains of multi-drug resistant E. coli. PLoS One. 2011;6(10):15. doi: 10.1371/journal.pone.0025825 WOS:000299081800007.
  39. 39. Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49(8):3198–202. doi: 10.1128/aac.49.8.3198-3202.2005. WOS:000230950700016. pmid:16048925
  40. 40. Rossolini GM, Zanchi A, Chiesurin A, Amicosante G, Satta G, Guglielmetti P. Distribution of cphA or related carbapenemase-encoding genes and production of carbapenemase activity in members of the genus Aeromonas. Antimicrob Agents Chemother. 1995;39(2):346–9. WOS:A1995QE77700013. pmid:7726495
  41. 41. Tacao M, Correia A, Henriques IS. Low Prevalence of Carbapenem-Resistant Bacteria in River Water: Resistance Is Mostly Related to Intrinsic Mechanisms. Microb Drug Resist. 2015;21(5):497–506. doi: 10.1089/mdr.2015.0072. WOS:000362181200001. pmid:26430939
  42. 42. Livermore D. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34(5):634–40. pmid:11823954
  43. 43. European Food Safety Authority (EFSA) BIOHAZ Panel. Scientific opinion on carbapenem resistance in food animal ecosystems. EFSA Journal. 2013;11(12).
  44. 44. Dortet L, Agathine A, Naas T, Cuzon G, Poirel L, Nordmann P. Evaluation of the RAPIDEC® CARBA NP, the Rapid CARB Screen®, and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2015;(Epup ahead of print).
  45. 45. Evans BA, Amyes SGB. OXA beta-Lactamases. Clin Microbiol Rev. 2014;27(2):241–63. doi: 10.1128/cmr.00117-13. WOS:000334076500004. pmid:24696435
  46. 46. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect. 2014;20(9):821–30. doi: 10.1111/1469-0691.12719. WOS:000343824500012. pmid:24930781
  47. 47. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother. 2001;45(6):1860–7. doi: 10.1128/aac.45.6.1860-1867.2001. WOS:000168842700038. pmid:11353638
  48. 48. Ribeiro VB, Linhares AR, Zavascki AP, Barth AL. Performance of quantification of Modified Hodge Test: an evaluation with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae isolates. BioMed research international. 2014;2014:139305. doi: 10.1155/2014/139305. MEDLINE:24790988. pmid:24790988
  49. 49. Pournaras S, Poulou A, Tsakris A. Inhibitor-based methods for the detection of KPC carbapenemase-producing Enterobacteriaceae in clinical practice by using boronic acid compounds. J Antimicrob Chemother. 2010;65(7):1319–21. doi: 10.1093/jac/dkq124. WOS:000279926500001. pmid:20395214
  50. 50. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440–58. doi: 10.1128/cmr.00001-07. WOS:000248268400004. pmid:17630334